Publication Cover
Immunological Investigations
A Journal of Molecular and Cellular Immunology
Volume 52, 2023 - Issue 4
120
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Interleukin-35 Enhances Regulatory T Cell Function by Potentially Suppressing Their Transdifferentiation into a T Helper 17-Like Phenotype in Kawasaki Disease

&

References

  • Agarwal S, Agrawal DK. 2017. Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol. 13(3):247–58.
  • Cho J, Kim S, Yang DH, Lee J, Park KW, Go J, Hyun CL, Jee Y, Kang KS. 2018. Mucosal immunity related to FOXP3 + regulatory T cells, Th17 cells and cytokines in pediatric inflammatory Bowel disease. J Korean Med Sci. 33(52):e336.
  • Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, et al. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 13(3):290–99.
  • Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 450(7169):566–69.
  • Diller ML, Kudchadkar RR, Delman KA, Lawson DH, Ford ML. 2016. Balancing inflammation: the link between Th17 and regulatory T cells. Mediators Inflamm. 2016:6309219. doi:10.1155/2016/6309219.
  • Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. 2010. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 30(1):80–89.
  • Franco A, Shimizu C, Tremoulet AH, Burns JC. 2010. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity. 43(4):317–24.
  • Franco A, Touma R, Song Y, Shimizu C, Tremoulet AH, Kanegaye JT, Burns JC. 2014. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity. 47(2):95–104.
  • Furuno K, Yuge T, Kusuhara K, Takada H, Nishio H, Khajoee V, Ohno T, Hara T. 2004. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr. 145(3):385–90.
  • Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limon P, Paiva RS, Ching T, et al. 2015. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 523(7559):221–25.
  • Gunduz E, Sermet S, Musmul A. 2016. Peripheral blood regulatory T cell levels are correlated with some poor prognostic markers in newly diagnosed lymphoma patients. Cytometry B Clin Cytom. 90(5):449–54.
  • Guo J, Gu M, Zhang W, Liu Y, Qian C, Deng A. 2018. Aberrant IL-35 levels in patients with primary Sjogren’s syndrome. Scand J Immunol. 88(5):e12718.
  • Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC. 2015. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 70(3):310–18.
  • He W, Hao S, Dong X, Zhang D, Jia Z. 2022. Circulating cytokine profile and modulation of regulatory T cells in chronic hepatitis B patients with type 2 diabetes mellitus. Bosn J Basic Med Sci. doi:10.17305/bjbms.2022.7525
  • Huang Q, Wang Y, Si C, Zhao D, Wang Y, Duan Y. 2017. Interleukin-35 modulates the imbalance between regulatory T cells and T helper 17 cells in enterovirus 71-induced hand, foot, and mouth disease. J Interferon Cytokine Res. 37(12):522–30.
  • Jia S, Li C, Wang G, Yang J, Zu Y. 2010. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol. 162(1):131–37.
  • Koizumi K, Hoshiai M, Moriguchi T, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, et al. 2019. Plasma exchange downregulates activated monocytes and restores regulatory T cells in Kawasaki disease. Ther Apher Dial. 23(1):92–98.
  • Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-Hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H. 2014. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 20(1):62–68.
  • Lee GR. 2018. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci. 19(3):730.
  • Liao HT, Lin YF, Tsai CY, Chou CT. 2015. Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment. Joint Bone Spine. 82(6):423–27.
  • Liu S, Zhang Q, Shao X, Wang W, Zhang C, Jin Z. 2017. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. Int Immunopharmacol. 50:87–94.
  • Liu ZZ, Sun GQ, Hu XH, Kwak-Kim J, Liao AH. 2017. The transdifferentiation of regulatory T and Th17 cells in autoimmune/inflammatory diseases and its potential implications in pregnancy complications. Am J Reprod Immunol. 78(2):e12657.
  • Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, Zheng Y, Wang W, Deng L, Shen L. 2016. Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget. 7(45):73003–15.
  • Matsubara T, Ichiyama T, Furukawa S. 2005. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 141(3):381–87.
  • McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, et al. 2017. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 135:e927–99. doi:10.1161/CIR.0000000000000484.
  • Miyara M, Sakaguchi S. 2007. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 13(3):108–16.
  • Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, Kihara K, Fujii Y. 2018. Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer. 16(6):e1151–58.
  • Niedbala W, Wei X-Q, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. 2007. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 37(11):3021–29.
  • Nyirenda MH, Sanvito L, Darlington PJ, O’Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B. 2011. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol. 187(5):2278–90.
  • Paradowska-Gorycka A, Wajda A, Romanowska-Prochnicka K, Walczuk E, Kuca-Warnawin E, Kmiolek T, Stypinska B, Rzeszotarska E, Majewski D, Jagodzinski PP, et al. 2020. Th17/Treg-related transcriptional factor expression and cytokine profile in patients with rheumatoid arthritis. Front Immunol. 11:572858. doi:10.3389/fimmu.2020.572858.
  • Rasouli M, Heidari B, Kalani M. 2014. Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease. Immunol Lett. 162(1):269–75.
  • Rife E, Gedalia A. 2020. Kawasaki disease: an update. Curr Rheumatol Rep. 22(10):75.
  • Shao Y, Yang WY, Saaoud F, Drummer C, Sun Y, Xu K, Lu Y, Shan H, Shevach EM, Jiang X, et al. 2021. IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms. JCI Insight. 6(19):e152511.
  • Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D. 2009. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 131(1):109–18.
  • Singh S, Jindal AK, Pilania RK. 2018. Diagnosis of Kawasaki disease. Int J Rheum Dis. 21(1):36–44.
  • Su Y, Feng S, Luo L, Liu R, Yi Q. 2019. Association between IL-35 and coronary arterial lesions in children with Kawasaki disease. Clin Exp Med. 19(1):87–92.
  • Sun M, Xing H. 2021. Interleukin-35 regulates peripheral T cell activity in patients with Kawasaki disease. Int Immunopharmacol. 96:107642. doi:10.1016/j.intimp.2021.107642.
  • Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A. 2018. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer. 143(9):2105–15.
  • Wang D, Lei L. 2021. Interleukin-35 regulates the balance of Th17 and Treg responses during the pathogenesis of connective tissue diseases. Int J Rheum Dis. 24:21–27. doi:10.1111/1756-185X.13962.
  • Xing H, Tian G. 2020. Increased interleukin-35 suppresses peripheral CD14(+) monocytes function in patients with Kawasaki disease. BMC Immunol. 21(1):17.
  • Yang L, Jia S, Shao X, Liu S, Zhang Q, Song J, Wang W, Jin Z. 2019. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J. 16(1):48.
  • Ye C, Yano H, Workman CJ, Vignali DAA. 2021. Interleukin-35: structure, function and its impact on immune-related diseases. J Interferon Cytokine Res. 41(11):391–406.
  • Yu N, Li X, Song W, Li D, Yu D, Zeng X, Li M, Leng X, Li X. 2012. CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation. 35(6):1773–80.
  • Zhang Y, Lian JQ, Huang CX, Wang JP, Wei X, Nan XP, Yu HT, Jiang LL, Wang XQ, Zhuang Y, et al. 2010. Overexpression of Toll-like receptor 2/4 on monocytes modulates the activities of CD4(+)CD25(+) regulatory T cells in chronic hepatitis B virus infection. Virology. 397(1):34–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.